Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL H WAKEFIELD

Allopathic & Osteopathic Physicians Family Medicine

NPI
1740221647
CMS profile
305581
Location
KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,504.85

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,504.85 102

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL H WAKEFIELD

NPI 1740221647 · CMS profile ID 305581

Allopathic & Osteopathic Physicians / Family Medicine

KNOXVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740221647?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL H WAKEFIELD, NPI 1740221647, CMS profile ID 305581. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740221647?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAUL H WAKEFIELD, NPI 1740221647, CMS profile ID 305581. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740221647?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAUL H WAKEFIELD, NPI 1740221647, CMS profile ID 305581, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740221647?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $1,504.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $13.0106/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783470637 CMS
Novo Nordisk Inc $19.0906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811661531 CMS
Amarin Pharma Inc. $13.3406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815390061 CMS
AbbVie Inc. $12.6506/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217125 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8806/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323511 CMS
SANOFI-AVENTIS U.S. LLC $14.7206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843447867 CMS
Esperion Therapeutics, Inc. $17.6706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838432445 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424440 CMS
Novo Nordisk Inc $13.1805/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810866489 CMS
Novo Nordisk Inc $15.0005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810720465 CMS
AbbVie Inc. $11.8405/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217123 CMS
GlaxoSmithKline, LLC. $15.4805/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802010201 CMS
AbbVie Inc. $11.3205/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217121 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.0405/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323507 CMS
AbbVie Inc. $13.3904/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217119 CMS
AbbVie Inc. $19.3904/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217117 CMS
Biohaven Pharmaceuticals, Inc. $14.9404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852651313 CMS
GlaxoSmithKline, LLC. $13.6804/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802786479 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.0204/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424442 CMS
AbbVie Inc. $9.6404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217115 CMS
AbbVie Inc. $18.7304/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217113 CMS
Novo Nordisk Inc $14.1503/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811537903 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1303/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424444 CMS
E.R. Squibb & Sons, L.L.C. $16.5903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783470605 CMS
AbbVie Inc. $13.9403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217111 CMS
Ironwood Pharmaceuticals, Inc $12.9703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855100117 CMS
Amgen Inc. $22.1203/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826407923 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.9103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323503 CMS
AbbVie Inc. $13.6103/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217109 CMS
Merck Sharp & Dohme Corporation $15.1503/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848320531 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.5003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323499 CMS
GlaxoSmithKline, LLC. $13.5502/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802432345 CMS
AbbVie Inc. $20.3302/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217107 CMS
Amarin Pharma Inc. $16.0902/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815390063 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.3402/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424446 CMS
AbbVie Inc. $8.0002/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217105 CMS
Novo Nordisk Inc $16.8102/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810720461 CMS
Esperion Therapeutics, Inc. $18.1102/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838432443 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.3802/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424448 CMS
AbbVie Inc. $23.4102/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217103 CMS
Novo Nordisk Inc $14.9502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811661527 CMS
Lilly USA, LLC $13.5902/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818725303 CMS
Amarin Pharma Inc. $17.0701/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815246195 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323495 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9.9101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763424450 CMS
AbbVie Inc. $11.4301/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796217101 CMS
GlaxoSmithKline, LLC. $13.4701/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802906587 CMS
Biohaven Pharmaceuticals, Inc. $14.1901/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852651311 CMS
Novo Nordisk Inc $17.2901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811249683 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.9101/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820323491 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,451.38 111
PY2020 $1,340.83 93
PY2021 $1,504.85 102
PY2022 $1,550.06 99
PY2023 $1,968.52 122
PY2024 $4,316.44 148
PY2025 $2,120.11 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,850,259.23 273
PY2024 Principal investigator $380,807.17 19
PY2023 Principal investigator $511,560.32 69
PY2022 Principal investigator $476,635.73 35
PY2021 Principal investigator $298,808.36 26
PY2020 Principal investigator $307,763.03 63
PY2019 Recipient $1,024.58 8
PY2019 Principal investigator $475,867.39 122

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

273 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,154.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568781
Principal investigator 1 Genentech, Inc. $12,387.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568837
Principal investigator 1 Genentech, Inc. $122.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568943
Principal investigator 1 Hoffmann-La Roche Limited $12,428.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569415
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 12/16/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808078
Principal investigator 1 PFIZER INC. $87.75 12/13/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228724726
Principal investigator 1 PFIZER INC. $135.00 12/12/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228737983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.50 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,473.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,713.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,767.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274270
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $449.28 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,328.75 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,097.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $648.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,506.95 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,689.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,109.15 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $741.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,063.55 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,140.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,830.35 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $627.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,530.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274829
Principal investigator 1 Genentech, Inc. $16,803.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568756
Principal investigator 1 Hoffmann-La Roche Limited $7,582.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569330
Principal investigator 1 Hoffmann-La Roche Limited $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,520.85 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,600.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,222.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269287
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726841
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726843
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726845
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726849
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726851
Principal investigator 1 PFIZER INC. $4,000.00 11/26/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228715629
Principal investigator 1 Genentech, Inc. $500.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567869
Principal investigator 1 Genentech, Inc. $1,500.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568196
Principal investigator 1 Genentech, Inc. $31,315.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,013.90 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264457
Principal investigator 1 Genentech, Inc. $61.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567810
Principal investigator 1 Genentech, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568133
Principal investigator 1 Genentech, Inc. $8,676.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568519
Principal investigator 1 Hoffmann-La Roche Limited $11,373.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,905.07 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263529
Principal investigator 1 Genentech, Inc. $61.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568039
Principal investigator 1 Genentech, Inc. $9,189.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568071
Principal investigator 1 Genentech, Inc. $61.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568075
Principal investigator 1 Genentech, Inc. $358.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568093
Principal investigator 1 Hoffmann-La Roche Limited $31,625.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,247.20 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261249
Principal investigator 1 Genentech, Inc. $28,940.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567669
Principal investigator 1 Genentech, Inc. $67,361.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567735
Principal investigator 1 Genentech, Inc. $3,790.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567751
Principal investigator 1 Genentech, Inc. $122.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567830
Principal investigator 1 Genentech, Inc. $15,315.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567915
Principal investigator 1 Genentech, Inc. $19,939.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567930
Principal investigator 1 Genentech, Inc. $30,292.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567981
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567991
Principal investigator 1 Genentech, Inc. $4,309.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568344
Principal investigator 1 Genentech, Inc. $4,118.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568391
Principal investigator 1 Genentech, Inc. $3,063.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568419
Principal investigator 1 Genentech, Inc. $12,073.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568580
Principal investigator 1 Genentech, Inc. $718.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568583
Principal investigator 1 Genentech, Inc. $15,315.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568682
Principal investigator 1 Hoffmann-La Roche Limited $54,502.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211568985
Principal investigator 1 Hoffmann-La Roche Limited $4,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569053
Principal investigator 1 Hoffmann-La Roche Limited $12,320.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,973.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,246.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,125.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,482.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,926.80 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.65 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $696.33 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,243.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,346.80 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,188.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.01 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,029.84 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,265.69 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259159
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726831
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726833
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726835
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726837
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726839
Principal investigator 1 PFIZER INC. $4,864.00 10/31/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228741051
Principal investigator 1 Amgen Inc. $58,735.93 10/24/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228,875.76 10/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250579
Principal investigator 1 Amgen Inc. $838.23 10/08/2025 Non-covered Recipient Entity
SUMMIT MEDICAL GROUP
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648890
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726817
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726819
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726825
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726827
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726813
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 09/24/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726815
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,642.30 09/18/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808076
Principal investigator 1 Genentech, Inc. $49,031.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235241
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726775
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726777
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726779
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726781
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726783
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726801
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $314.40 09/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230611
Principal investigator 1 Genentech, Inc. $2,707.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211566925
Principal investigator 1 Genentech, Inc. $169.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567102
Principal investigator 1 Genentech, Inc. $6,126.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567126
Principal investigator 1 Genentech, Inc. $8,719.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567204
Principal investigator 1 Genentech, Inc. $3,063.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567257
Principal investigator 1 Genentech, Inc. $3,981.15 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567265
Principal investigator 1 PFIZER INC. $117,375.75 08/21/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228723598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.01 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,384.80 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,150.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228457
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,362.65 08/06/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808072
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726765
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726767
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726769
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726771
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726773
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726795
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726799
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $943.92 07/31/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808070
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 07/28/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726803
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726805
Principal investigator 1 Boehringer Ingelheim International GmbH $803.00 07/28/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726807
Principal investigator 1 Boehringer Ingelheim International GmbH $24.36 07/28/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726809
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 07/28/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726811
Principal investigator 1 Genentech, Inc. $11,626.00 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567164
Principal investigator 1 PFIZER INC. $45,862.20 07/11/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228773487
Principal investigator 1 Genentech, Inc. $9,387.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567016
Principal investigator 1 Genentech, Inc. $6,735.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,784.43 07/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212905
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726787
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726789
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726791
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726793
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726797
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,237.45 06/26/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808068
Principal investigator 1 F. Hoffmann-La Roche AG $12,414.80 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566640
Principal investigator 1 Hoffmann-La Roche Limited $16,320.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568960
Principal investigator 1 Hoffmann-La Roche Limited $2,958.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568967
Principal investigator 1 F. Hoffmann-La Roche AG $13,796.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,837.57 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.65 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206611
Principal investigator 1 Amgen Inc. $12,899.04 06/09/2025 Non-covered Recipient Entity
ACCELLACARE OF KNOXVILLE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638700
Principal investigator 1 F. Hoffmann-La Roche AG $143.10 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566373
Principal investigator 1 F. Hoffmann-La Roche AG $963.90 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566396
Principal investigator 1 F. Hoffmann-La Roche AG $583.20 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566409
Principal investigator 1 F. Hoffmann-La Roche AG $606.60 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566496
Principal investigator 1 F. Hoffmann-La Roche AG $175.50 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566692
Principal investigator 1 F. Hoffmann-La Roche AG $753.30 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566795
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726749
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726751
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726753
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726755
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726757
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726759
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726761
Principal investigator 1 F. Hoffmann-La Roche AG $225.00 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566381
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 05/27/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726763
Principal investigator 1 F. Hoffmann-La Roche AG $2,500.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566432
Principal investigator 1 F. Hoffmann-La Roche AG $3,129.30 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566719
Principal investigator 1 F. Hoffmann-La Roche AG $10,108.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566807
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,345.85 05/09/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808066
Principal investigator 1 F. Hoffmann-La Roche AG $2,661.00 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,887.13 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193795
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726735
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726737
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726739
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726743
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726745
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726747
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,400.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $48.00 05/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808064
Principal investigator 1 F. Hoffmann-La Roche AG $10,899.00 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,427.46 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,213.73 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189077
Principal investigator 1 PFIZER INC. $2,000.00 04/17/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228800981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,854.92 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182086
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726723
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726725
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726727
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726729
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726731
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,213.73 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180946
Principal investigator 1 AstraZeneca Pharmaceuticals LP $362,268.56 03/26/2025 Non-covered Recipient Entity
ACCELLACARE
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185544713
Principal investigator 1 F. Hoffmann-La Roche AG $4,328.00 03/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566300
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,929.80 03/14/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,292.65 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.00 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156788
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726705
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726707
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726709
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726711
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726713
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726715
Principal investigator 1 F. Hoffmann-La Roche AG $6,102.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,083.94 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153078
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726693
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726695
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726697
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726699
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726701
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726703
Principal investigator 1 Boehringer Ingelheim International GmbH $1.86 01/27/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726717
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726719
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,795.50 01/27/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808058
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,402.00 01/17/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.25 01/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148071
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 01/08/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $452.25 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $560.25 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145768
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726687
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726689
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726691
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Accellacare Of Knoxville
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220726721